| Abstract: | Successful therapeutics for inflammatory bowel disease (IBD) must be able to reverse effectively the complex processes involved in the manifestation of inflammatory pathology in intact tissues. Although studies of human tissue samples are important to confirm the biological rationale for developing a particular therapeutic, in vivo rodent models of IBD provide a biological ‘flask’ in which therapeutics can be tested in a more representative setting. Moreover, gene targeting and transgenic technologies in rodents have exponentially increased the repertoire of available IBD models and provided insight into possible contributions that certain genes may have in the pathogenesis of disease. These models have been key in generating the current arsenal of biological therapeutics that are available, or are presently under investigation, for the treatment of IBD patients. |
